Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
7.67
+0.63 (8.95%)
Aug 12, 2026, 4:00 PM EDT - Market closed
Entrada Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 99.28 | 90.39 | 101.21 | 67.6 | 45.16 | 291.06 |
Short-Term Investments | 123.73 | 205.3 | 318.79 | 284.37 | 143.56 | - |
Cash & Short-Term Investments | 223.01 | 295.7 | 420 | 351.97 | 188.71 | 291.06 |
Cash Growth | -37.01% | -29.59% | 19.33% | 86.51% | -35.16% | 645.46% |
Accounts Receivable | 0.82 | 1.18 | 3.68 | 5.88 | - | - |
Other Current Assets | 8.88 | 9.38 | 16.36 | 11.92 | 21.16 | 7.64 |
Total Current Assets | 232.7 | 306.25 | 440.04 | 369.77 | 209.88 | 298.7 |
Net Property, Plant & Equipment | 62.76 | 67.76 | 82.05 | 92.68 | 33.02 | 6.26 |
Other Long-Term Assets | 3.41 | 3.36 | 4.23 | 6.74 | 9.16 | 0.87 |
Total Assets | 298.88 | 377.38 | 526.32 | 469.19 | 252.06 | 305.83 |
Accounts Payable | 3.75 | 2.29 | 4.26 | 3.28 | 5.99 | 0.71 |
Accrued Expenses | 13 | 17.68 | 13.34 | 11.33 | 7.58 | 6.01 |
Current Portion of Leases | 4.45 | 4.14 | 7.56 | 7.91 | 8.41 | - |
Unearned Revenue | 0.17 | 0.34 | 13.65 | 132.26 | - | - |
Other Current Liabilities | - | - | 0.67 | 4.02 | - | - |
Total Current Liabilities | 21.37 | 24.45 | 39.48 | 158.8 | 21.97 | 6.72 |
Long-Term Leases | 44.1 | 46.79 | 51.65 | 60.32 | 17.53 | - |
Other Long-Term Liabilities | - | - | 6.51 | 7.72 | - | 0.4 |
Total Long-Term Liabilities | 44.1 | 46.79 | 58.16 | 68.04 | 17.53 | 0.4 |
Total Liabilities | 65.47 | 71.25 | 97.64 | 226.83 | 39.5 | 7.12 |
Common Stock | 0 | 0 | 0 | 0 | 0 | 0 |
Additional Paid-in Capital | 588.92 | 578.57 | 558.06 | 437.13 | 402.89 | 392.38 |
Accumulated Other Comprehensive Income | 0.07 | 0.65 | -0.04 | 0.2 | -2.06 | - |
Retained Earnings | -355.57 | -273.09 | -129.34 | -194.97 | -188.29 | -93.67 |
Total Common Shareholders' Equity | 233.41 | 306.13 | 428.68 | 242.36 | 212.55 | 298.72 |
Shareholders' Equity | 233.41 | 306.13 | 428.68 | 242.36 | 212.55 | 298.72 |
Total Liabilities & Equity | 298.88 | 377.38 | 526.32 | 469.19 | 252.06 | 305.83 |
Total Debt | 48.54 | 50.93 | 59.21 | 68.23 | 25.94 | 0 |
Net Cash (Debt) | 174.46 | 244.77 | 360.79 | 283.74 | 162.78 | 291.06 |
Net Cash Growth | -41.70% | -32.16% | 27.16% | 74.31% | -44.08% | 645.46% |
Net Cash Per Share | 4.18 | 5.92 | 9.25 | 8.59 | 5.20 | 46.44 |
Book Value | 233.41 | 306.13 | 428.68 | 242.36 | 212.55 | 298.72 |
Book Value Per Share | 5.59 | 7.40 | 10.99 | 7.33 | 6.79 | 47.66 |
Tangible Book Value | 233.41 | 306.13 | 428.68 | 242.36 | 212.55 | 298.72 |
Tangible Book Value Per Share | 5.59 | 7.40 | 10.99 | 7.33 | 6.79 | 47.66 |